Regulus Therapeutics (RGLS) Institutional Ownership → A once-in-a-century investment opportunity (From Stansberry Research) (Ad) Free RGLS Stock Alerts $2.08 +0.08 (+4.00%) (As of 03:16 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Regulus Therapeutics (NASDAQ:RGLS)CurrentInstitutional OwnershipPercentage92.38%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$57.49MNumber ofInstitutional Sellers(last 12 months)0 Get RGLS Insider Trade Alerts Want to know when executives and insiders are buying or selling Regulus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RGLS Institutional Buying and Selling by Quarter Ad Huge Alerts**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!Click for Zack's full report Regulus Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/17/2024 RA Capital Management L.P.6,250,000$18M0.2%N/A9.547% 5/15/2024 NEA Management Company LLC6,467,802$18.63M1.1%N/A9.879% 5/10/2024 Vanguard Group Inc.740,215$2.13M0.0%+158.4%1.131% 5/7/2024CVI Holdings LLC1,406,250$4.05M3.9%N/A2.148% 4/22/2024 Vivo Capital LLC5,000,000$14.40M1.1%N/A7.638% 2/5/2024 Victory Capital Management Inc.271,736$348K0.0%+16.5%1.344% Get the Latest News and Ratings for RGLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/13/2023 FMR LLC2,922,600$4.03M0.0%+32.4%14.454% 11/6/2023 Victory Capital Management Inc.233,207$322K0.0%+5.3%1.197% 8/14/2023 Prelude Capital Management LLC40,660$60K0.0%N/A0.209% 9/16/2022 Federated Hermes Inc.2,904,826$6.01M0.0%-90.0%19.850% 8/16/2022 DAFNA Capital Management LLC555,555$1.15M0.3%-90.0%3.797% 8/12/2022 Ikarian Capital LLC105,341$217K0.0%-91.8%0.722% 8/1/2022 Victory Capital Management Inc.221,506$459K0.0%-90.1%1.517% 7/19/2022Commonwealth Equity Services LLC22,000$45K0.0%-83.2%0.151% 2/14/2022 DAFNA Capital Management LLC5,555,555$1.75M0.4%N/A6.382% 1/19/2022Asymmetry Capital Management L.P.2,731,044$860K0.5%+94.9%3.137% 11/15/2021 GSA Capital Partners LLP64,708$45K0.0%-68.6%0.074% 11/4/2021Asymmetry Capital Management L.P.1,401,491$968K0.6%-3.4%1.610% 10/29/2021Commonwealth Equity Services LLC111,000$76K0.0%+38.8%0.128% 9/17/2021Virtu Financial LLC79,193$64K0.0%N/A0.091% 8/27/2021 Endurant Capital Management LP2,607,674$2.12M0.6%+9.7%2.996% 8/16/2021 State Street Corp176,494$144K0.0%N/A0.203% 8/13/2021 Geode Capital Management LLC589,196$479K0.0%+54.3%0.786% 8/13/2021 Vanguard Group Inc.3,095,237$2.52M0.0%-3.9%4.131% 8/12/2021 Lido Advisors LLC57,500$47K0.0%N/A0.077% 8/11/2021Commonwealth Equity Services LLC80,000$65K0.0%+300.0%0.107% 8/10/2021Strategic Wealth Advisors Group LLC74,800$61K0.0%N/A0.100% 8/5/2021 GSA Capital Partners LLP206,265$168K0.0%N/A0.275% 7/31/2021Asymmetry Capital Management L.P.1,450,777$1.18M0.8%-26.9%1.936% 7/15/2021 Focused Wealth Management Inc200,000$163K0.0%+100.0%0.267% 5/19/2021 Squarepoint Ops LLC159,804$249K0.0%+1,477.7%0.213% 5/17/2021 Endurant Capital Management LP2,376,557$3.71M1.0%N/A3.172% 5/17/2021 Ikarian Capital LLC1,245,989$1.94M0.1%N/A1.663% 5/17/2021 Atom Investors LP337,228$526K0.1%N/A0.450% 5/17/2021 Goldman Sachs Group Inc.18,049$28K0.0%-68.0%0.024% 5/12/2021 Northern Trust Corp117,654$184K0.0%+198.4%0.157% 5/12/2021 Geode Capital Management LLC381,892$595K0.0%+493.5%0.510% 5/11/2021 Acadian Asset Management LLC465,678$726K0.0%N/A0.622% 5/11/2021Asymmetry Capital Management L.P.1,985,472$3.10M1.6%N/A2.650% 5/4/2021Commonwealth Equity Services LLC20,000$31K0.0%N/A0.027% Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide5/4/2021 Victory Capital Management Inc.2,227,199$3.47M0.0%+345.4%2.976% 5/3/2021 Focused Wealth Management Inc100,000$156K0.0%N/A0.134% 2/10/2021 Renaissance Technologies LLC449,200$606K0.0%N/A1.147% 2/5/2021 BlackRock Inc.49,788$68K0.0%-23.2%0.127% 2/2/2021 Grimes & Company Inc.54,511$74K0.0%+127.1%0.139% 2/2/2021 GYL Financial Synergies LLC51,376$69K0.0%N/A0.131% 2/1/2021 Victory Capital Management Inc.499,989$675K0.0%N/A1.277% 10/20/2020 Wedbush Securities Inc.70,204$36K0.0%+241.2%0.193% 8/14/2020 BVF Inc. IL1,450,000$988K0.1%-9.0%6.892% 8/7/2020Virtu Financial LLC84,348$57K0.0%N/A0.401% 5/12/2020 Rockefeller Capital Management L.P.84,642$39K0.0%-22.9%0.402% (Data available from 1/1/2016 forward) RGLS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RGLS shares? During the previous two years, 12 institutional investors and hedge funds held shares of Regulus Therapeutics. The most heavily invested institutionals were NEA Management Company LLC ($18.63M), RA Capital Management L.P. ($18M), Vivo Capital LLC ($14.40M), Federated Hermes Inc. ($6.01M), CVI Holdings LLC ($4.05M), FMR LLC ($4.03M), and Vanguard Group Inc. ($2.13M).Learn more on RGLS's institutional investors. What percentage of Regulus Therapeutics stock is owned by institutional investors? 92.38% of Regulus Therapeutics stock is owned by institutional investors. Learn more on RGLS's institutional investor holdings. Which institutional investors have been buying Regulus Therapeutics stock? The following institutional investors have purchased Regulus Therapeutics stock in the last 24 months: NEA Management Company LLC ($6.47M), RA Capital Management L.P. ($6.25M), Vivo Capital LLC ($5M), CVI Holdings LLC ($1.41M), FMR LLC ($716K), Vanguard Group Inc. ($453.78K), and Victory Capital Management Inc. ($50.23K). How much institutional buying is happening at Regulus Therapeutics? Institutional investors have bought a total of 20,384,726 shares in the last 24 months. This purchase volume represents approximately $57.49M in transactions. Which Regulus Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Regulus Therapeutics stock in the last 24 months: Federated Hermes Inc. ($26.14M), DAFNA Capital Management LLC ($5M), Victory Capital Management Inc. ($2.01M), Ikarian Capital LLC ($1.18M), and Commonwealth Equity Services LLC ($109K). How much institutional selling is happening at Regulus Therapeutics? Institutional investors have sold a total of 34,447,753 shares in the last 24 months. This volume of shares sold represents approximately $71.31M in transactions. Related Companies: Rigel Pharmaceuticals Major Shareholders Alimera Sciences Major Shareholders Merrimack Pharmaceuticals Major Shareholders Bolt Biotherapeutics Major Shareholders Emergent BioSolutions Major Shareholders XOMA Major Shareholders Vanda Pharmaceuticals Major Shareholders Verastem Major Shareholders Lexicon Pharmaceuticals Major Shareholders Seres Therapeutics Major Shareholders This page (NASDAQ:RGLS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldUrgent Nvidia WarningAltimetryThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
